ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0112

Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis

Quan Li1 and Proton Rahman2, 1University of Toronto, Toronto, Canada, 2Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada

Meeting: ACR Convergence 2025

Keywords: Genome Wide Association Studies, proteomics, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: While numerous proteins have been linked to psoriatic arthritis (PsA), the causal nature of these associations remains unconfirmed. This study aims to employ a Mendelian randomization (MR) approach to evaluate whether circulating plasma protein levels, derived from extensive international databases, are causally associated with PsA.

Methods: The study analyzed 1,553 PsA patients and 147,221 controls, all of whom had undergone genome-wide association scans, as identified from the FinnGen consortium. Large-scale plasma protein quantitative trait locus (pQTL) data were sourced from the UK Biobank Proteomics Project (UKB-PPP) (2,923 unique proteins), the INTERVAL study (2,995 unique proteins), and the Icelandic study (Ferkingsatad et al. 2021) with (4,719 proteins). Potential protein candidates were identified based on SNP associations with proteins (p < 5×10^-8), LD clumping to identify independent pQTLs for each protein (r^2 < 0.001), and defining SNPs when the leading SNP was located within 500kb of the transcription site of the protein-coding gene. A two-sample MR was then performed, using the Wald ratio for genes with one SNP and inverse variance weighting (IVW) for genes with more than one SNP. Appropriate MR sensitivity and pleiotropy analyses were conducted.

Results: A total of 19 unique proteins were identified as being associated with the risk of PsA. UKB-PPP dataset revealed four proteins linked to an increased risk of PsA (ATP6V1G2, LTA, HLA-E, APOF) and five proteins associated with a decreased risk (IL12A_IL12B, AGER, MICB_MICA, IL12B, HCG22) (Table 1). The INTERVAL dataset identified five proteins correlated with an elevated risk of PsA (HLA-DRB9, TNXB, HLA-DQB1, HLA-DRB1, HLA-DQA2) and three proteins linked to a reduced risk (IL12B, P4HA2, HLA-DQA1) (Table 1). From Ferkingsatad et al. 2021 dataset, MR identified five proteins significantly associated with PsA (C2,TNXB,HSPA1A and APOF increased PsA risk, while AGER decreased the risk, Table 2).A protein-protein interaction network was constructed using the STRING database, with a required interaction score of >0.4, illustrating the connections among these proteins. Notably, many of these proteins were found within the drug repurposing hub, therapeutic target database, and druggable genome compendium.

Conclusion: This proteome-wide MR study identified 19 unique proteins associated with PsA risk, offering novel insights into the disease’s pathogenesis. These prioritized proteins also present potential druggable targets, warranting further investigation to explore novel therapeutic opportunities. More in depth studies are needed to assess the role and utility of these proteins.

Supporting image 1Table 1

Supporting image 2Table 2

Supporting image 3Figure 1


Disclosures: Q. Li: None; P. Rahman: Abbott, 2, AbbVie, 2, Amgen, 2, BMS, 2, Celgene, 2, Eli Lilly, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, UCB, 2.

To cite this abstract in AMA style:

Li Q, Rahman P. Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/proteome-wide-mendelian-randomization-identifies-therapeutic-targets-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteome-wide-mendelian-randomization-identifies-therapeutic-targets-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology